Kinetic seals $1.7bn deal with LifeCell and tags on new biosurgery division
This article was originally published in Clinica
Executive Summary
Advanced wound care company Kinetic Concepts is to buy tissue repair product manufacturer LifeCell in a cash transaction worth $1.7bn, a move that will enable Kinetic to consolidate its presence in the fast-growing biosurgery market.
You may also be interested in...
Allergan Gets Regen Med Assets, Acelity Gets Cash Boost Post-IPO Dump
Allergan has agreed to acquire Acelity's LifeCell division for $2.9bn. The deal will give Allergan entry to the regenerative medicine sector and expand its aesthetics portfolio, while the substantial cash consideration should console Acelity after ditching plans for an IPO.
Allergan Adds Accretive Aesthetics Assets In $2.9bn LifeCell Acquisition
Allergan will pay $2.9bn in cash for LifeCell, a division of Acelity, adding its first regenerative medicine portfolio and marking its first commercial-stage deal in more than a year. The company hopes to exploit the surgical products for aesthetic uses beyond breast reconstruction.
Finance Watch: Adlai Nortye Raises $97.5m In IPO, Brings US Total To 18
Public Company Edition: Cancer-focused Adlai Nortye launched a concurrent initial public offering and private placement, while four other drug developers announced or completed SPAC mergers. Also, Sobi grossed $540m in a rights issue and Immunovant followed early data with a $450m FOPO.